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A recent article in Cell shows that vitamin D receptor activation reprograms reactive stroma in the tumor
microenvironment to a less inflammatory, quiescent state and is associated with increased drug retention,
tumor response, and survival in pancreatic cancer models. Stroma reprogramming, as opposed to ablation,
may emerge as a new treatment paradigm.It has been known for some time that
carcinomas are associated with a reac-
tive stroma microenvironment (Rønnov-
Jessen et al., 1996). Reactive stroma
usually initiates early in cancer progres-
sion, co-evolves with the cancer, and
represents a host response to disrupted
epithelial homeostasis. In effect, the
reactive stroma response is a rather
generic response, ostensibly to serve a
repair-centric function. The persistence
of this response is what is observed in
fibrosis disorders and during cancer
progression. Less clear are the specific
cell types, their origins, and how the
biology of reactive stroma affects tumor
progression. Collectively, this reactive
stroma has been referred to as carci-
noma-associated fibroblasts, myofibro-
blasts, or stellate cells (Apte et al.,
2004; Orimo and Weinberg, 2006; Von-
laufen et al., 2008). The majority of
studies have shown that reactive stroma
generaly promotes tumors, yet specific
mechanisms are not understood. The
biology affected by the stromal compart-
ment in cancer is likely to be quite
complex and involve a balance among
tumor-promoting and tumor-inhibiting
mechanisms. Nevertheless, the notion
of targeting the reactive stroma within
the tumor microenvironment as a meansof inhibiting cancer progression is an
attractive one.
Perhaps one of the most important per-
spectives regarding reactive stroma was
noted by Dvorak years ago, that cancers
are like ‘‘wounds that do not heal’’
(Dvorak, 1986). The biology of wound
repair is very complicated and is charac-
terized by pro-growth conditions that
require reactive stromal cells, followed
by a return to a normal differentiation
state. This process involves a resolution
of the reactive, pro-growth repair state
to one of more normal tissue quiescence
and biology. Hence, stromal reprogram-
ming is a part of normal wound repair
biology. If, as Dvorak pointed out, cancers
are like wounds that do not heal, then it
can be surmised that the stromal reprog-
ramming that instructs the stroma back
to differentiation during wound repair sim-
ply does not normally occur in cancer.
Considerable evidence in the literature
supports this concept, which is well out-
lined by Sherman et al. (2014) in a recent
issue of Cell. As aptly pointed out in
this article, in addition to tumor-pro-
moting functions, the persistent stromal
response has also been shown to inhibit
effective drug delivery and influence pat-
terns of therapeutic resistance in pancre-
atic cancer.Sherman et al. (2014) show that the
vitamin D receptor (VDR) is a critical
regulator of pancreatic stellate cells, the
reactive stroma observed in pancreatic
cancer. Importantly, this study shows
that VDR activation results in a reprog-
ramming of reactive stroma and reduced
inflammatory markers typically associ-
ated with fibrosis. In pancreatic tumor
models, this VDR-mediated stromal re-
programming resulted in increased drug
(gemcitabine) availability and reduced tu-
mor volume. Remarkably, use of the VDR
ligand resulted in a 57% increase in ani-
mal survival as compared to gemcitabine
treatment only. Effectively, this study
suggests that VDR activation resolves
the reactive stroma phenotype to one
that is noninflammatory and quiescent.
In essence, a reprogramming of the
stroma to a state more common of
normal homeostasis, such as would
occur naturally during completion of
normal wound healing. In this regard,
it would seem that VDR activation in
pancreatic cancer changes the tumor’s
status from being a wound that does
not heal, as cited by Dvorak, to a wound
that is partially healed in the important
stromal compartment.
The overall importance of the Sherman
et al. (2014) study is underscored by the, October 13, 2014 ª2014 Elsevier Inc. 451
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Previewssuggestion that ‘‘Vitamin D priming’’ may
be an important adjuvant in the treat-
ment of pancreatic cancer via enabling
chemotherapeutic response as a result
of stromal reprogramming. Ablation of
reactive stroma or complete inhibition
of reactive stroma formation has previ-
ously been suggested as a way to inhibit
cancer progression. However, recent
studies suggest that ablation of reactive
stroma may not be very effective in
treating pancreatic cancer (Amakye
et al., 2013; O¨zdemir et al., 2014; Rhim
et al., 2014). In addition, this ablation-
centric paradigm may neither be easily
attainable in patients nor the most natu-
ral way to modulate or resolve stromal
reactions. The important new paradigm
that evolves from the Sherman et al.
(2014) study is the perspective that a
reprogramming switch in the biology of452 Cancer Cell 26, October 13, 2014 ª2014reactive stroma may be a more effective
way to ensure efficient drug delivery
and inhibit chemotherapeutic resistance
mechanisms. Not only was this reprog-
ramming attainable, it was achieved by
activating a native VDR with an analog
ligand, a rather natural approach. These
seminal observations are truly paradigm
shifting and may change the way we
think about targeting the tumor microen-
vironment in order to influence cancer
progression.REFERENCES
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Human bladder cancers harbor deletions and point mutations in genes coding for Notch receptors and pro-
teins involved in Notch signaling. This leads to elevatedMAPK pathway activation, as direct Notch-mediated
transcription of MAPK phosphatase DUSP is lost. These bladder tumors, with impaired Notch signaling, also
show basal differentiation.Bladder cancer, a common tumor asso-
ciated with smoking, causes approxi-
mately 150,000 deaths worldwide each
year. The vast majority of these tumors
are derived from urothelium, a stratified
epithelial structure lining the urine-
exposed surface of the bladder. A num-
ber of distinct bladder tumor types have
been characterized, including papillary
urothelial carcinomas, which are usually
low-grade/localized lesions with excel-
lent prognosis, as well as carcinoma
in situ (CIS) and muscle-invasive urothe-
lial carcinomas. Squamous cell carci-
nomas (SCCs) also represent a signifi-
cant, but variable, fraction of bladdercancers. Indeed, SCCs typically repre-
sent less than 5% of total bladder cancer
cases; however, schistosomiasis infec-
tions or irritation and inflammation asso-
ciated with frequent catheter use can in-
crease the incidence of this disease.
Interestingly, two groups used lineage-
tracing in a BBN [N-butyl-N-(4-hydroxy-
butyl)nitrosamine]-induced mouse model
of bladder cancer to identify the cell of
origin for most bladder cancers (Shin
et al., 2014; Van Batavia et al., 2014).
For example, Van Batavia et al. found
that papillary tumors derive from inter-
mediate layer epithelial progenitor cells,
whereas flat aggressive lesions like CIS,muscle-invasive tumors, and SCC of
the bladder arise through transformation
of cytokeratin 5/p63-expressing cells in
the basal layer (Van Batavia et al.,
2014). Shin et al. showed that basal cells,
which also express Shh, are absolutely
required for CIS and invasive tumor for-
mation (Shin et al., 2014). Surprisingly,
muscle-invasive tumors form at the
expense of SCC in Trp53 heterozygous
mutant mice (Van Batavia et al., 2014).
Over the past several years, a
number of groups have reported on
efforts to define the mRNA andmicroRNA
gene expression profiles and pro-
teomic profiles as well as the mutations,
